p53 Small-Molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts

Eduard B. Dinca,1,2 Kan V. Lu,1,2 Jann N. Sarkaria,1,2 Russell O. Pieper,1,2 Michael D. Prados,1,2 Daphne A. Haas-Kogan,1,3 Scott R. VandenBerg,1,2,4 Mitchel S. Berger,1,2 and C. David James1,2

1Brain Tumor Research Center and Departments of *Neurological Surgery, †Radiation Oncology, and ‡Pathology, University of California San Francisco, San Francisco, California; and ‡Graduate Program in Molecular Neuroscience and 1,2Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota

Abstract

In this study, we investigated the precursor and active forms of a p53 small-molecule inhibitor for their effects on temozolomide (TMZ) antitumor activity against glioblastoma (GBM), using both in vitro and in vivo experimental approaches. Results from in vitro cell viability analysis showed that the cytotoxic activity of TMZ was substantially increased when p53 wild-type (p53wt) GBMs were cotreated with the active form of p53 inhibitor, and this heightened cytotoxic response was accompanied by increased poly(ADP-ribose)polymerase cleavage as well as elevated cellular phospho-H2AX. Analysis of the same series of GBMs, as intracranial xenografts in athymic mice, and administering corresponding p53 inhibitor precursor, which is converted to the active compound in vivo, yielded results consistent with the in vitro analyses: TMZ + p53 inhibitor precursor cotreatment of three distinct p53wt GBM xenografts resulted in significant enhancement of TMZ antitumor effect relative to treatment with TMZ alone, as indicated by serial bioluminescence monitoring as well as survival analysis (P < 0.001 for cotreatment survival benefit in each case). Mice receiving intracranial injection with p53wild GBM showed similar survival benefit from TMZ treatment regardless of the presence or absence of p53 inhibitor precursor. In total, our results indicate that the p53 active and precursor inhibitor pair enhances TMZ cytotoxicity in vitro and in vivo, respectively, and do so in a p53-dependent manner. [Cancer Res 2008;68(24):10034–9]

Introduction

Attempts and approaches at manipulating p53 activity in treating human cancer have been numerous and diverse. For example, viral-mediated introduction and expression of wild-type (wt) TP53 in p53-defective tumor cells has been extensively investigated for more than a decade, including through clinical trial activity (1). Alternative approaches for increasing tumor cell wt p53 activity include the use of small molecules that promote p53 transcription and the use of compounds that inhibit p53 interaction with murine double minute 2 (2).

Perhaps because of it being counter to conventional thinking about the role of tumor suppressor genes in cancer etiology, as well as being counterintuitive about the way in which tumor suppressor genes are viewed in relation to the treatment of cancer, there has been relatively little research directed toward the development of antitumor therapeutic strategies that include a p53 inhibitory component. Indeed, as a monotherapy, such a treatment approach could promote increased tumor cell proliferation and decreased tumor cell apoptosis. However, the potential consequences of attempted cell cycling by tumor cells with damaged DNA, resulting from genotoxic therapy with concurrent inhibition of p53, are interesting to consider. In fact, results from several studies involving in vitro investigation of tumor cell lines support enhanced cytotoxic chemotherapeutic response in association with p53 inhibition (3–6). Furthermore, with respect to GBM, the p53 small-molecule inhibitor pifithrin-α, which was identified nearly a decade ago in association with a chemical library screen (7), has been shown to enhance the in vitro cytotoxic effect of temozolomide (TMZ), a DNA alkylator, as well as the cytotoxic effect of chloroethylating nitrosoureas such as carmustine (8, 9).

In addition to reasons described above, in vivo investigation of p53 small-molecule inhibitors, as part of a cancer treatment strategy, has been hindered due to limitations imposed by physical properties of the pifithrin-α reference compound (10). Recently, however, derivatives of the reference compound were described with respect to their potential in vivo use (11). In the current study, we have tested one of these compounds, using an intracranial GBM xenograft therapy-response model, and present results indicating its enhancement of TMZ antitumor activity in vivo and in a manner that is dependent on tumor cell p53 status.

Materials and Methods

In vitro experiments. GBM xenografts used in this study have previously been described (12, 13), as has the modification of xenografts for bioluminescence imaging (13). Xenograft cells were cultured as nonadherent neurospheres in neurobasal media (Invitrogen), whereas U87 cells (American Type Culture Collection) were propagated as monolayer cultures in DMEM supplemented with 10% FCS. Temozolomide (TMZ; obtained from Temodar from Schering-Plough) and active-form p53 inhibitor (cyclic pifithrin-α p-nitro, Calbiochem) were dissolved in DMSO (Sigma-Aldrich) as 20 and 5 mmol/L stock solutions, respectively. For bioluminescence viability analysis, cells were treated with DMSO, TMZ (added to concentrations of 50 or 100 μmol/L), p53 inhibitor (concentration of 10 μmol/L), or a combination of TMZ and p53 inhibitor, with chemical agents added to media once a day for 3 consecutive days. Cell culture specimens were examined for bioluminescence signal using a Xenogen imaging system (Caliper Life Sciences), following the addition of 25 μL of 20 mg/ml sodium luciferin (Gold Biotechnology) in PBS (Invitrogen).
Flow cytometry cell cycle analysis. U87 cells were treated once a day for 3 d with DMSO only, 10 μmol/L p53 inhibitor, 50 or 100 μmol/L TMZ, or 50 or 100 μmol/L TMZ + 10 μmol/L p53-inhibitor. At 1, 4, and 7 d after final treatment, the cells were harvested, washed with PBS, and fixed with cold 70% ethanol. Cells were stained with propidium iodide and examined by flow cytometry (BD LSR II, Becton-Dickinson), with results analyzed using Flowjo software.

Immunoblot analysis. Primary antibodies used for immunoblot analysis (previously described; see ref. 13) were for detection of poly(ADP-ribose) polymerase (Cell Signaling Tech), phospho-histone H2AX (Cell Signaling Tech), p53 (Sigma-Aldrich), p21 (Santa Cruz Biotech), MGMT (R&D Systems), or β-tubulin (Millipore). Secondary antibodies used were antimouse or antirabbit (Cell Signaling Tech) or antigoat (Santa Cruz Biotech).

Methylation-specific PCR. Analysis of MGMT promoter methylation was as described by Esteller and colleagues (14). PCR products were resolved in 4.5% agarose gels (NuSieve 3:1, Lonza, Inc.) and were subsequently stained with ethidium bromide.

In vivo experiments. Procedures used for intracranial tumor therapy-response experiments, including monitoring of tumor growth and response to therapy by bioluminescence imaging, have previously been described (13). Treatment groups for the experiments reported here were as follows: 3 d i.p. DMSO and oral suspension vehicle (Oral Plus, Paddock Laboratories) by gavage (control group); 3 d 10 mg/kg TMZ in oral suspension vehicle for GBM 12, GBM 14, and U87, and 50 mg/kg for GBM 26; 3 d 0.25 mg p53 inhibitor precursor (pifithrin-α p-nitro, Calbiochem) in DMSO by i.p. injection; or 3 d combination TMZ and p53 inhibitor as indicated for their administration as single agents.

Results

GBM xenograft explant cultures were incubated with TMZ +/- cyclic pifithrin-α p-nitro (Supplementary Fig. S1; see ref. 11) to assess the in vitro effects of this p53 inhibitor on tumor cell TMZ cytotoxic response. Results for p53wt GBM 26 showed substantial decreases in viable cell number resulting from TMZ + p53 inhibitor cotreatments, in relation to cells treated with TMZ alone (Fig. 1A and B). Importantly, cyclic pifithrin-α p-nitro alone showed no antitumor effect. In contrast to the results for GBM 26, GBM 12 cells, which express no endogenous p53 (p53null; see ref. 12), showed similar cytotoxic response to TMZ irrespective of the presence or absence of the p53 inhibitor (Fig. 1C). In contrast to the others (11), cyclic pifithrin-α p-nitro inhibits DNA damage-associated induction of the negative cell cycle regulator p21, but only in p53wt cells (Fig. 1D). In addition, and consistent with the p53 small-molecule inhibitor treatments, pretreating cells with p53 siRNA enhanced the TMZ cytotoxic response of GBM 26 cells, relative to pretreating cells with nonspecific siRNA, whereas GBM 12 cells responded similarly to TMZ whether preincubated with p53 or nonspecific siRNA (Supplementary Fig. S2).

Figure 1. In vitro cell viability analysis of GBM xenograft explant cultures subjected to TMZ +/- p53 inhibitor treatments. A, GBM 26 cells were treated with TMZ only (black) at the indicated concentrations or with TMZ + 10 μmol/L cyclic pifithrin-α p-nitro (gray). Treatments were administered once a day for 3 consecutive days (each treatment group consisting of triplicate samples); 4 d following final treatment, the luminescence of each treatment group was determined (B). Columns, average values for each treatment group; bars, SE. *, P < 0.05; TMZ only versus TMZ + p53 inhibitor treatments. C, the same experimental design as described for GBM 26 was used for assessing p53null GBM 12 cell response to treatments, with results presented as indicated for A. D, immunoblot results for p21 expression in cells treated with TMZ +/- p53 inhibitor (p53i). TMZ (100 μmol/L) induces p21 expression in p53wt cells (GBM 26), and this induction is suppressed through concurrent treatment with p53 inhibitor (incubations as described for A and C). In contrast to the results for GBM 26, p21 is not detected in p53null GBM 12 cells, irrespective of treatment (shown) or lack of treatment with TMZ. Replicate samples for this analysis yielded similar results.
cotreatment versus treatment with 100 μmol/L TMZ only were 1.97, 2.25, and 1.54 at days 1, 4, and 7 following final treatment, respectively (Fig. 2A and B). Consistent with the GBM xenograft explant culture cytotoxic response results described above (Fig. 1),

results from U87 flow cytometry analysis showed little difference in cell cycle distributions between U87 treated with cyclic pifithrin-α p-nitro and mock-treated control cells (Fig. 2A).

Immunoblot analysis of U87 cells incubated with TMZ +/− cyclic pifithrin-α p-nitro showed increased poly(ADP-ribose) polymerase cleavage resulting from combined treatment, in comparison with cells treated with the same concentration of TMZ alone (Fig. 2C), thereby suggesting increased caspase activity in association with the enhanced cytotoxic response to TMZ + p53 inhibitor. Heightened apoptotic response to combination treatment was also indicated by increased phospho-H2AX in cells incubated with TMZ + p53 inhibitor, relative to cells incubated with the same concentration of TMZ alone. Levels of p53 protein were similar between culture treatments (Fig. 2C), consistent with the inhibitory activity of pifithrin-α compounds involving suppression of existing p53 activity, rather than suppression of p53 expression.

Previous study of pifithrin-α p-nitro derivatives has revealed that 2-aminothiazole salt cyclization (Supplementary Fig. S1A and S1B) is required for the formation of active p53 inhibitor, and that this cyclization occurs spontaneously in vivo, albeit over a period of several hours (11). Because active-form p53 inhibitors have relatively short half-lives in vivo, it has been suggested that the kinetics of inactive, open-form precursor conversion to corresponding cyclized, active-form compound can be used to advantage for achieving prolonged cell exposure to active state inhibitors in vivo and thereby achieve prolonged p53 inhibitory effect (11). In accord with this line of reasoning, we investigated the open-form precursor of cyclic pifithrin-α p-nitro (Supplementary Fig. S1A) for effect on TMZ in vivo antitumor activity, using a previously described intracranial GBM xenograft therapy-response model (13). Mice injected with p53<sup>wt</sup> tumor cells (GBM14, GBM 26, and U87) or with cells from p53<sup>null</sup> GBM 12 were monitored for luminescence increases indicative of log-phase growth of injected cells, at which time TMZ (gavage) and p53 inhibitor precursor (i.p. injection) were administered singularly or concurrently once a day for 3 consecutive days (treatment periods indicated by vertical gray columns, Fig. 3A and B). For mice injected with p53<sup>wt</sup> GBM,

![Figure 2. Flow cytometry and immunoblot analysis of U87 cells subjected to TMZ +/- cyclic pifithrin-α p-nitro inhibitor treatments. A, cell treatments were as follows: control, DMSO only; p53 inhibitor only, 10 μmol/L cyclic pifithrin-α p-nitro administered daily for 3 consecutive days; TMZ only, 50 or 100 μmol/L TMZ administered daily for 3 consecutive days; TMZ + p53 inhibitor, 50 or 100 μmol/L TMZ + 10 μmol/L p53 inhibitor administered daily for 3 consecutive days. Cells were harvested from individual plates on the days indicated (values represent days following final treatment administration) and prepared for flow cytometry analysis. Associated flow cytometry profiles show similar amounts of and predominant G<sub>1</sub> phase cell fractions in control and p53 inhibitor only samples at each time point, whereas time-dependent increases in proportion of sub-G<sub>1</sub> cell fractions are evident in the TMZ only and the TMZ + p53 inhibitor series (black lines beneath each column of profiles indicate, from left to right, the positions of the sub-G<sub>1</sub>, G<sub>1</sub>, and G<sub>2</sub>-M cell fractions). Results shown are for 100 μmol/L TMZ treatments. B, bar graph showing sub-G<sub>1</sub> ratios for TMZ + p53 inhibitor versus TMZ only treatments and indicating that the proportion of sub-G<sub>1</sub> cells is largest, at each time point, in cultures subjected to combined TMZ + p53 inhibitor treatment. C, immunoblot results for U87 cells subjected to control and p53 inhibitor only treatments, as described above, and to combination treatments with 50 or 100 μmol/L TMZ +/- p53 inhibitor. Results are for cells d after final treatment administration and show the presence or absence of cleaved poly(ADP-ribose) polymerase (PARP), presence or absence of phospho-H2AX, and relative amounts of p53 protein; each tubulin result is presented beneath the corresponding result obtained from the same filter, and addresses total protein loading variation. Note the lack of effect of TMZ on p53 expression (middle and far right lanes of p53 immunoblot), which is consistently observed in tumors expressing p53.](cancerres.aacrjournals.org)
survival was significantly extended by combined TMZ + p53 inhibitor treatment, relative to TMZ treatment alone, and this effect was observed for three p53<sup>wt</sup> tumors (P < 0.001 for each; Fig. 3A; Table 1). Survival benefits were consistent with corresponding results from bioluminescence monitoring, which revealed prolonged decrease of p53<sup>wt</sup> intracranial tumor luminescence in mice receiving TMZ + p53 inhibitor (Fig. 3B). It is worth noting that p53 inhibitor precursor enhancement of TMZ cytotoxicity was observed irrespective of p53<sup>wt</sup> GBM sensitivity to TMZ alone, as TMZ-resistant GBM 26, with unmethylated MGMT promoter and highly expressed MGMT protein, and GBM 14 and U87, in which MGMT promoter methylation is accompanied by a lack of detectable MGMT protein (Fig. 3C and D), all showed significantly increased response to combination treatment. Conversely, mice with p53<sup>mut</sup> GBM 12 intracranial tumor did not experience significant survival benefit from combined TMZ + p53 inhibitor precursor treatment in comparison with mice receiving treatment with TMZ only (Fig. 3D; Table 1).

Discussion

Research for examining potential clinical applications of p53 small-molecule inhibitors has often involved experimental paradigms that address the protection of normal cells, rather than determining effects on tumor cell response to therapy that includes p53 inhibition. Specifically, there is considerable interest about whether p53 small-molecule inhibitors can be used to spare normal cells from p53-mediated apoptosis that occurs from oxidative stress during stroke, renal injury, or cardiac arrest (15), as well as from the genotoxic effects of cancer treatments (7). Small-molecule inhibition of p53 in tumor cells, for enhancing the anticancer effects of therapy, has not attracted much attention, although there is ample related evidence in support of this concept. This support, however, primarily stems from the use of viral gene product expression (4) and RNA interference (3, 6) to suppress tumor cell p53 function, and the perspective of the associated studies has been to investigate the role of p53 as a determinant of tumor cell response to cytotoxic therapy, rather than to pursue p53 as a target for augmenting the effects of therapy.

In the current study, we have contrasted p53<sup>wt</sup> versus p53<sup>mut</sup> GBM xenograft response to cytotoxic therapy that includes the use of a small-molecule inhibitor of p53. Significantly extended survival benefit from combination therapy was evident among a series of mice with intracranial p53<sup>wt</sup> GBM, whereas mice with intracranial p53<sup>mut</sup> GBM did not experience survival benefit from combination therapy. The issue about the response of p53 missense mutants to p53 inhibitor treatment is complex due to the diversity of p53 mutations in human cancer, the distinct transcriptional effects of individual p53 mutations, and the transcription-independent cellular activities of mutant p53 (16–18). Current studies are in progress to address the variability of p53 missense mutant GBM response to p53 inhibitor–augmented cytotoxic therapy.

There are numerous candidates to consider as mediators of p53 inhibitor–enhanced cytotoxic response, with our results currently supporting more extensive investigation of p53 inhibitor–mediated suppression of p21 (Fig. 1D), as well as investigation of apoptotic response effectors that are inferred by our preliminary results (Fig. 2; Supplementary Fig. S3). There are, of course, additional aspects of this cytotoxic response to be investigated, one of which is indicated in a recent report showing that p53 inhibition can suppress TMZ-associated induction of MGMT (19). In the case of the tumor cell sources used here, this could be a contributing factor associated with p53 inhibitor enhancement of TMZ cytotoxicity against GBM 26, for which MGMT is unmethylated and expressed, but is probably less likely for GBM 14 and U87 tumors, for which MGMT is presumably silenced through MGMT promoter methylation (Fig. 3C and D).

In addition to investigating the molecular biology of pathways and proteins associated with enhanced TMZ cytotoxic effect through concurrent p53 inhibition, the identification of surrogate markers that can be used to assess p53 inhibitor activity in tumors is critically important. The ability to analyze tumors for temporal variations in the expression and/or activity of biomarkers that respond to p53 inhibition, in combination with corresponding analysis of tumor extracts for temporal variations in p53 inhibitor content (e.g., through use of high-performance liquid chromatography), will provide key information about inhibitor pharmacodynamics for optimizing combination therapy dosing and sequencing.

Results presented here provide some basis for considering the subgroup of GBM that would benefit from therapy that includes p53 inhibition. As concerns this point, it is significant that p53 inhibition enhances TMZ cytotoxicity in p53<sup>wt</sup> tumors irrespective of their sensitivity to TMZ monotherapy. Consequently, this therapeutic approach could conceivably benefit the two thirds of

---

**Table 1. Summary of TMZ +/- p53 inhibitor xenograft studies**

<table>
<thead>
<tr>
<th>Tumor</th>
<th>Control</th>
<th>p53i only</th>
<th>TMZ only</th>
<th>TMZ + p53i</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>GBM 14</td>
<td>28.1</td>
<td>27.6</td>
<td>76.8</td>
<td>&gt;142 (&gt;85.0%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>29.5</td>
<td>28.5</td>
<td>73.5</td>
<td>145 (97.3%)</td>
<td></td>
</tr>
<tr>
<td>GBM 26</td>
<td>48.3</td>
<td>48.6</td>
<td>51.1</td>
<td>82.9 (62.2%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>48.0</td>
<td>49.0</td>
<td>54.0</td>
<td>85.0 (57.4%)</td>
<td></td>
</tr>
<tr>
<td>U87</td>
<td>29.9</td>
<td>29.6</td>
<td>36.9</td>
<td>53.7 (45.5%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>30.0</td>
<td>30.0</td>
<td>37.0</td>
<td>51.0 (37.8%)</td>
<td></td>
</tr>
<tr>
<td>GBM 12</td>
<td>15.8</td>
<td>16.3</td>
<td>50.9</td>
<td>52.0 (2.2%)</td>
<td>0.178</td>
</tr>
<tr>
<td></td>
<td>16.0</td>
<td>16.0</td>
<td>50.5</td>
<td>54.0 (6.9%)</td>
<td></td>
</tr>
</tbody>
</table>

NOTE: Mean (black) and median (gray) values in days for duration of symptom-free survival of mice receiving intracranial injection of indicated tumor cells and receiving indicated treatments. Values in parentheses represent mean or median percent survival difference in comparing TMZ only versus TMZ + p53 inhibitor (p53i). P values for TMZ only versus TMZ + p53i survival comparisons are indicated.
Figure 3. Intracranial xenograft therapy response to TMZ +/- p53 inhibitor precursor treatments. Groups of 32 mice received intracranial tumor cell injection (300,000 cells per mouse) using luciferase-modified GBM, and at times when log-phase growth was indicated by bioluminescence imaging (BLI), each series of mice was randomized into four treatment groups with eight mice per group, and treatments were initiated. Treatment groups were as follows: control (i.p. injection of DMSO + gavage with TMZ suspension vehicle, once a day for 3 d; broken black line); p53 inhibitor precursor only (0.25 mg in 50 µL DMSO administered by i.p. injection once a day for 3 d; broken gray line); TMZ only (10 mg/kg administered in oral suspension vehicle by gavage, once a day for 3 d for GBM 12, GBM 14, and U87, and 50 mg/kg once a day for 3 d for GBM 26; solid black line); or combination TMZ + p53 inhibitor (solid gray line), as indicated for each agent's use alone. Treatment periods are indicated by a vertical gray column in each of the graphs in A and B. A, survival plots for each experiment show that combined TMZ + p53 inhibitor precursor treatment significantly extends symptom-free survival relative to TMZ alone in mice with p53 wt tumor (GBM 26, GBM 14, and U87), but not in mice with p53 null GBM 12. P values indicated at the top of each graph are for TMZ alone versus TMZ + p53 inhibitor precursor comparisons. B, corresponding bioluminescence imaging curves, with plots beginning at day of treatment initiation, and showing either lack of effect or suppression of luminescence resulting from TMZ +/- p53 inhibitor precursor treatments (mean luminescence values plotted for each treatment group, with SE indicated). For the plots involving GBM 26, GBM 14, and U87, the number of days between log-phase tumor growth for TMZ only and TMZ + p53 inhibitor precursor treatment groups is indicated, and the order of these differences (largest to smallest) is consistent with the order of corresponding length of survival benefit (see Table 1). To the far right are luminescence intensity overlay images. For mice with intracranial GBM 14, GBM 26, or U87, mice with lowest and highest intracranial tumor luminescence in TMZ only and TMZ + p53 inhibitor treatment groups, respectively, are shown, with images captured at days indicated by the arrowheads along the TMZ + p53 inhibitor plots in A. For GBM 12, which does not show additional response to combination treatment beyond that associated with TMZ alone, image overlays are shown for mice that define the median tumor luminescence from each group at the day indicated by the arrowhead over the corresponding graph in A. C, MGMT promoter methylation analysis showing lack of methylation in GBM 26, which has corresponding detectable protein expression (D) and displays resistance to TMZ alone (A). Results for tumors GBM 12, GBM 14, and U87 show the presence of MGMT promoter methylation and corresponding lack of detectable protein by immunoblot.
GBM patients whose tumors are of wt p53 status (20). Looking beyond the GBM-specific interests of this report, it seems plausible that the results of our study are generalizable to other types of cancer as well as to other types of genotoxic therapy.

An additional observation associated with this study is that TMZ + p53 inhibitor treatment is without adverse effect, as evidenced by autopsy analysis of animal subjects that showed no abnormal cellular proliferation in tissue from mice receiving TMZ + p53 inhibitor treatment (e.g., gastrointestinal tract; Supplementary Fig. S4]). This, in combination with the long-term survival of mice that received TMZ + p53 inhibitor (see GBM 14 results in Fig. 3A), as well as the similarity in group body weight patterns for TMZ only and TMZ + p53 inhibitor treated mice (Supplementary Fig. S4B), suggests a lack of acute as well as long-term effects of this therapy. Nonetheless, the simultaneous administration of a DNA-damaging agent with an inhibitor of DNA repair could promote undesirable systemic side effects, including the development of independent cancers in other organs. To address this concern, future research should perhaps include strategies for the local delivery of inhibitor to tumor to minimize side effects resulting from combination therapy. Irrespective of the methods of delivery that are used, the long-term consequences of this therapeutic approach will need to be investigated in detail.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 5/7/2008; revised 8/28/2008; accepted 9/18/2008.

Grant support: NIH grants N049720, CA097257, CA108961, CA127716, and CA108001.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

References

p53 Small-Molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts

Eduard B. Dinca, Kan V. Lu, Jann N. Sarkaria, et al.


Updated version Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/68/24/10034

Supplementary Material Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2008/12/10/68.24.10034.DC1

Cited articles This article cites 20 articles, 11 of which you can access for free at: http://cancerres.aacrjournals.org/content/68/24/10034.full.html#ref-list-1

Citing articles This article has been cited by 5 HighWire-hosted articles. Access the articles at: /content/68/24/10034.full.html#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.